Cardiac amyloidosis is an under-recognized and potentially fatal cause of heart failure and other cardiovascular manifestations. It is therefore increasingly important for clinicians providing care for patients with cardiovascular disease to recognize the signs and symptoms of cardiac amyloidosis, understand effective strategies for diagnosis, and be aware of important management advances. The Canadian Cardiovascular Society/Canadian Heart Failure Society Position Statement provides evidence based recommendations supporting the early recognition, and optimal diagnostic approach and management strategies for patients with cardiac amyloidosis.
In this workshop session, members of the CCS/CHFS Amyloidosis panel will present key messages from the 2019 statement to highlight new evidence. Members will use example cases to discuss:
1. the symptomatic management of heart failure and other cardiovascular complications such as arrhythmia,
2. risk stratification and follow-up surveillance,
3. use of ATTR disease modifying therapies, and
4. optimal clinical care settings for patients with this complex multisystem disease.